New hope for kids with tough neuroblastoma: triple therapy trial launches
NCT ID NCT02914405
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a combination of three treatments—radioactive iodine (131-I-MIBG), an immunotherapy drug (nivolumab), and an antibody (dinutuximab beta)—in children whose high-risk neuroblastoma has come back or not responded to standard therapy. The main goal is to see if the combination is safe and tolerable. About 44 children across hospitals in the UK, Germany, and the US will take part. If the full-dose combination is safe, the study will also look for signs that it shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nivolumab and dinutuximab beta combined with radioactive iodine (131-I-MIBG)
- What this could lead to
- If this combination proves safe and effective, it could offer a new treatment option for children with hard-to-treat neuroblastoma.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so it is primarily testing safety. The combination may not work or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University College London Hospital
London, London, NW1 2BU, United Kingdom
-
University Hospital Southampton NHS Foundation Trust
Southampton, Hampshire, SO16 6YD, United Kingdom
-
University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital
Madison, Wisconsin, 53792, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a shorter chemo combo tame High-Risk neuroblastoma?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- Can AI read tumor slides to outsmart childhood cancer?
- Can a radioated molecule shrink untreatable neuroblastoma?
- Slowing down immunotherapy infusion may reduce pain in children with Tough-to-Treat neuroblastoma